TFRC and Alzheimer disease: Iron dysregulation is a well-established feature of AD pathology (Liu et al., 2018; Levi et al., 2024; Spotorno et al., 2020), and this study provides the first evidence linking abnormally low levels of CAMKK2, TF, and TFRC proteins to significantly increased iron content in the temporal cortices of AD patients compared to CN individuals.